HC Wainwright Issues Pessimistic Estimate for ENTA Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Stock analysts at HC Wainwright reduced their Q4 2026 earnings per share estimates for Enanta Pharmaceuticals in a report issued on Tuesday, May 12th. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings of ($0.80) per share for the quarter, down from their prior estimate of ($0.73). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ FY2028 earnings at ($3.24) EPS, FY2029 earnings at ($2.43) EPS and FY2030 earnings at ($2.21) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 68.72% and a negative net margin of 89.56%.The company had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million.

A number of other research analysts have also weighed in on ENTA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Rodman & Renshaw started coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $14.03 on Thursday. The business has a 50 day simple moving average of $13.64 and a 200 day simple moving average of $13.53. Enanta Pharmaceuticals has a 52-week low of $5.03 and a 52-week high of $17.15. The stock has a market cap of $407.14 million, a price-to-earnings ratio of -5.42 and a beta of 1.01.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. Sei Investments Co. boosted its stake in shares of Enanta Pharmaceuticals by 10.4% during the 1st quarter. Sei Investments Co. now owns 109,077 shares of the biotechnology company’s stock worth $1,378,000 after buying an additional 10,295 shares during the last quarter. Hillsdale Investment Management Inc. raised its holdings in Enanta Pharmaceuticals by 3.1% during the first quarter. Hillsdale Investment Management Inc. now owns 435,510 shares of the biotechnology company’s stock worth $5,500,000 after acquiring an additional 13,210 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in Enanta Pharmaceuticals during the fourth quarter valued at approximately $36,000. Virtu Financial LLC bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $220,000. Finally, Invesco Ltd. grew its stake in Enanta Pharmaceuticals by 325.2% in the fourth quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock valued at $4,003,000 after purchasing an additional 194,113 shares in the last quarter. 94.99% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.